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Abstract
Background Erythropoiesis-stimulating agents (ESAs) are biological molecules approved for the treatment of anemia associ-
ated with chronic renal failure. Biosimilars were licensed for use in Europe in 2007.
Aim This study aimed to compare the safety profile of biosimilars with respect to the reference product in a nephrology 
setting.
Methods A prospective study was conducted in four Italian regions between 1 October 2013 and 30 June 2015. The study 
population included patients aged ≥ 18 years undergoing hemodialysis and treated with epoetins as per the clinical practice 
of the participating centers. The two comparison cohorts included patients treated with either an originator or a biosimilar 
epoetin alfa. Each patient was followed up until occurrence of any safety outcome of interest (grouped into three major 
categories), switch to a different ESA product, transplant or peritoneal dialysis, death, or end of the study period, whichever 
came first.
Results Overall, 867 subjects were included in the study (originator: N = 423; biosimilar: N = 444). Biosimilar users were 
older than originator users (median age of 76 vs 64 years, respectively), more frequently affected by arrhythmia (29.3 vs 
22.5%), and less frequently candidates for transplantation (3.8 vs 18.2%). Cox-regression analysis showed no increase in 
risk of safety outcomes in biosimilar users, even after adjusting for confounding factors: 1.0 (95% confidence interval [CI] 
0.7–1.3) for any outcomes; 1.1 (95% CI 0.7–1.8) for problems related to dialysis device; 0.9 (95% CI 0.6–1.5) for cardio- and 
cerebro-vascular conditions; 0.9 (95% CI 0.6–1.5) for infections.
Conclusion This study confirms the comparable safety profiles of originator and biosimilar epoetin alfa drugs when used 
in patients receiving dialysis.
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Key Points 
We carried out an observational study to compare the 
safety of originator epoetin alfa and biosimilars in 
patients receiving dialysis.
The two cohorts of users were largely overlapping in the 
time-to-events: approximately 25% of users experienced 
a safety outcome within 6 months of observation and 
40% within 1 year.
Both unadjusted and adjusted estimates did not show 
any difference in the safety outcomes between the two 
cohorts.
Even though relevant to the clinical setting of dialysis, 
our findings provide further reassurance about the use of 
biosimilars in clinical practice.
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1 Introduction
Biosimilars represent one of the main factors contributing 
to the economic sustainability of health systems. Savings on 
pharmaceutical expenditure originate only partly from the 
lower price of biosimilars. In fact, a larger effect is obtained 
when the originators are forced to reduce their prices, in 
order to counter the increased prescriptions of biosimilars. 
The significant advantage for patients and communities is 
that financial resources may be more efficiently allocated to 
other uses, in particular making innovative medicines avail-
able to patients [1].
This positive outcome could be hampered by uncertainty 
about the comparability process conducted to obtain mar-
keting authorization for biosimilars. Despite the stringent 
regulatory requirements and the high standard of evidence 
required in the approval process [2], scientific societies and 
even regulators have expressed concerns regarding the safety 
and effectiveness of biosimilars [3, 4].
Providing prescribers with information about the rig-
orous steps of the approval process, as well as acquiring 
new evidence from clinical practice in order to corrobo-
rate the data obtained in the pre-registration phase, is 
essential for overcoming this resistance. Moreover, given 
the production process specificity of biological drugs, 
ongoing verification that the comparative risk–ben-
efit profile of originator drug and biosimilars remains 
unchanged over the years is useful.
Erythropoiesis-stimulating agents (ESAs) are one of the 
first therapeutic categories in which biosimilars became 
available. Although biosimilar ESAs were licensed for use in 
Europe in 2007 in the nephrology setting, their prescription 
has been relatively limited for many years. For instance, at 
the beginning of 2013, when the present study was planned, 
in Italy biosimilar products represented only 10.6% of the 
doses of the entire ESA category, and 20.7% of those of 
epoetin alfa [5].
Given the large number of patients, nephrology is one of 
the clinical areas that might increase the diffusion of bio-
similars because physicians have not only to choose which 
product is to be preferentially used in naïve patients, but also 
to decide whether switching between different products—
both originators and biosimilars—carries an additional risk 
for patients. To this end, contributing additional data derived 
from current practice was deemed helpful. Therefore, a post-
authorization observational study aimed at comparing the 
efficacy and safety of ESA products in patients undergoing 
dialysis treatment (ESAVIEW) was conducted in four Italian 
regions with the financial support of the Italian Medicines 
Agency [6]. The main objective of the study was to compare 
the safety of originator versus biosimilar epoetin alfa drugs 
in patients with chronic kidney disease (CKD).
2  Methods
2.1  Study Design and Population
This observational, multicenter, prospective cohort study 
was conducted in 26 hospitals of four Italian regions 
(Veneto, Liguria, Molise, and Sardegna) between 1 October 
2013 and 30 June 2015. The study population included all 
adult (≥ 18 years) CKD outpatients undergoing hemodialysis 
at least twice a week and who were treated with epoetins as 
per the clinical practice of the participating hospitals. The 
study population comprised both prevalent users (patients 
already on ESAs before inclusion in the study) and incident 
users (patients starting the use of ESA at inclusion). Each 
patient was followed for 12 months after the first (index) 
visit. Patients were excluded if they were involved in other 
clinical studies or did not provide inform consent.
2.2  Data Collection
Trained monitors were in charge of collecting information 
from the clinical charts and recording it in a web-based 
database. For each patient, the following baseline data were 
collected: age and gender; dry weight; primary kidney dis-
ease; dialysis frequency and type of vascular access; pre-
vious renal transplant and/or inclusion on the transplant 
list; comorbidities; investigation tests; and drugs. For more 
details on the baseline comorbidities considered in the study, 
refer to Online Resource 1 (see electronic supplementary 
material [ESM]). The study monitors updated some of the 
baseline data (e.g., dialysis frequency, inclusion on the trans-
plant list) and the results of investigation tests on a monthly 
basis.
2.3  Definition of Drug Exposure
Patients were classified as users of originator  (Eprex®) or 
biosimilar  (Binocrit® or  Retacrit®) epoetin alfa based on 
the ESA received at index visit. Date of administration, 
drug authorization code, and number of dosage units were 
recorded for each patient at every visit. Patients were con-
sidered as incident (new) users of epoetins if they were not 
already on treatment at the index visit (no information was 
collected to distinguish between ‘never users’ before the first 
visit and patients who had already received prescriptions of 
epoetins in the past).
2.4  Study Outcomes
Clinicians were expected to detail in the clinical records 
any adverse event that was reported by the patient and 
observed by the attending physician. Moreover, reasons 
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for any emergency department visit or hospitalization were 
recorded as adverse events. The study monitors coded the 
safety outcomes according to the Medical Dictionary for 
Regulatory Affairs (MedDRA; version 7.0). MedDRA pro-
vides a hierarchy for summarizing symptoms or diagnoses: 
coding of the events was carried out at each visit using the 
preferred term level.
Starting from individual safety outcomes, three major cat-
egories were agreed between the participating nephrologists 
and the research group in order to provide clinically mean-
ingful grouping with a sufficient number of events. The three 
categories were ‘Problems related to the dialysis device’ 
(i.e., arteriovenous fistula site complications, catheter-related 
complications, and infections of the vascular access), ‘Car-
dio and cerebrovascular events’ (i.e., coronary heart disease, 
arrhythmia, heart failure, cerebrovascular events, peripheral 
arterial occlusive disease, hemorrhage, and thrombosis), and 
‘Infections’ (i.e., pneumonia/respiratory tract infections, sep-
sis, and other infections). Arrhythmia was included as an 
outcome only if not reported at baseline. Heart failure and 
coronary heart disease were considered as events if not pre-
existing at baseline. A clinical chart reporting a bypass/stent 
for patients with coronary heart disease or a worsening heart 
condition in case of heart failure and myocardial infarction 
was accepted as a safety event. Online Resource 2 (see ESM) 
provides additional details about the study outcomes.
2.5  Follow‑Up
All patients were followed-up from the date of the index 
visit until the first of the following events: (i) any of the 
study outcomes; (ii) switch to a different ESA product; (iii) 
transplant or peritoneal dialysis; (iv) death; (v) end of the 
study period (12 months after the index visit).
2.6  Statistical Analysis
Characteristics of users of originator or biosimilar drugs 
were described through a χ2 test for categorical variables 
and a Mann–Whitney test or t test for continuous variables.
Survival curves by ESA exposure status were made using 
the Kaplan–Meier technique and compared using the log-
rank test.
The Cox proportional hazard model was used to compare 
the incidence rates of each outcome in the two cohorts and 
to estimate crude and adjusted hazard ratios (HRs) with 95% 
confidence intervals (CIs). All missing data were excluded 
from the analysis. The following baseline characteristics of 
patients were considered and tested as potential confound-
ers: age and gender; diagnosis leading to the renal failure; 
selected comorbidities retrieved at any time prior to the 
index visit; number of dialysis sessions per week; iron sup-
plementation; number of drugs taken by the patient (other 
than iron supplementation). We adopted a stepwise proce-
dure (significance for input 0.05 and removal 0.1) to select 
the characteristics to be included in the model for the risk 
adjustment.
The same analysis was conducted focusing only on inci-
dent users of epoetins. We also carried out three ancillary 
analyses comparing the two groups with regard to the last 
available hemoglobin (Hb) measurement, the need for trans-
fusion during follow-up, and the occurrence of death during 
the entire 12-month period.
The statistical analysis was performed using STATA 
software (version 11.2; StataCorp LP, College Station, TX, 
USA).
3  Results
3.1  Study Population
Overall, 1278 patients were treated with ESAs and were 
eligible for the study; 411 patients were excluded, mainly 
because they received other ESAs (i.e., darbepoetin alpha, 
 Aranesp®; methoxy polyethylene glycol-epoetin beta, 
 Mircera®; epoetin beta,  Neorecormon®), all without bio-
similars in the Italian market (Fig. 1).
Among the remaining 867 patients included in the 
analysis, 423 (48.8%) received the originator epoetin and 
444 (51.2%) the biosimilar ones (almost all subjects [440] 
received the  Binocrit® product). Patients on treatment with 
biosimilars were older than the originator users (76 vs 
64 years) (Table 1) and were more frequently affected by 
arrhythmia (29.3 vs 22.5%) and diabetes mellitus (34.9 vs 
28.6%) at baseline. Originator users more frequently had 
arteriovenous fistula (75.4 vs 61.9%) and previous renal 
transplant (14.2 vs 3.8%), they were more often on a waiting 
list for transplant (18.2 vs 3.8%), and had received dialysis 
for a longer time (36 vs 28 months).
We found no difference in the proportion of patients 
requiring iron supplementation at baseline, or in levels of 
Hb: 10.8 mg/dL and 10.9 mg/dL in users of biosimilar and 
originator epoetins, respectively.
3.2  Study Outcomes
The median duration of observation was slightly longer for 
patients receiving biosimilars (10.5 vs 8.5 months). Over-
all, 274 patients (31.6%) experienced at least one of the 
safety outcomes: 123 (29.1%) occurred among originator 
users and 151 (34.0%) among biosimilar users. The most 
frequent events were infections (100/867; 11.5%), followed 
by cardio and cerebrovascular conditions (92/867; 10.6%) 
and by problems related to the dialysis device (85/867; 
9.8%).
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The two cohorts were largely overlapping regarding time 
to events (Fig. 2). Approximately 25% of users had an event 
within 6 months of observation and 40% within 1 year. 
Moreover, no differences in the survival probability were 
highlighted when separately considering the three categories 
of events (Fig. 2).
Neither unadjusted nor adjusted estimates showed any 
difference in the study outcomes (Table 2). After adjusting 
for confounding factors, the HR estimates were 1.0 (95% CI 
0.7–1.3) for any outcomes; 0.9 (95% CI 0.6–1.5) for infec-
tions; 0.9 (95% CI 0.6–1.5) for cardio and cerebrovascular 
conditions; and 1.1 (95% CI 0.7–1.8) for problems related 
to the dialysis device. No statistically significant association 
was found for the individual outcomes within each category 
of events (Table 2).
3.3  Subgroup and Ancillary Analyses
Since our study cohort was mainly composed of prevalent 
users (about 88% of the study population), we also restricted 
the analysis to incident users (n = 102). The results were 
similar to those observed in the whole population, with 33 
patients (32.4%) experiencing at least one safety outcome 
and no statistically significant difference between biosimi-
lar and originator epoetin users (adjusted HR: 0.4; 95% CI 
0.1–1.1).
An ancillary analysis was also carried out to evaluate the 
differences in the number of patients needing transfusions: 
46 (10.3%) and 52 (12.3%) in the originator and biosimilar 
cohorts, respectively. With regard to the Hb level at the last 
measurement during follow-up, which can be considered as 
an indicator of quality of care, the average Hb was 11.0 mg/
dL in the biosimilar cohort and 11.1 mg/dL in the origina-
tor one.
During the 12-month follow-up, 127 deaths occurred in 
the study population (14.6%). In an intention-to-treat analy-
sis, the adjusted HR was 1.3 (95% CI 0.8–2.1) when compar-
ing biosimilar with originator users.
4  Discussion
4.1  Comparison with Previous Studies
The results from this study confirm the similarity in terms 
of safety between originator epoetin alpha and biosimilars 
when used in patients with CKD receiving dialysis. Spe-
cifically, no difference emerged between the two cohorts of 
users with regard to any kind of adverse events.
Phase III equivalence studies have been carried out in 
patients with CKD to obtain marketing authorization. 
These studies showed that biosimilars were therapeutically 
equivalent to the comparator epoetin alfa in changing mean 
absolute Hb; the two products also had a comparable safety 
profile in the intravenous treatment of anemia with regard 
to adverse events, serious adverse events, and death [7, 8].
Completed and ongoing observational post-authorization 
studies provide important additional information in a real-
world setting under conditions of greater heterogeneity of 
patients and clinical practices [9]. PASCO I and EPO-PASS 
were single-arm studies designed to investigate the incidence 
of adverse events of epoetin alfa biosimilars; these studies 
Fig. 1  Flow diagram of patients 
enrolled in the study. CKD 
chronic kidney disease, ESA 
erythropoiesis-stimulating 
agents
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Table 1  Characteristics of patients included in the study
IQR interquartile range, NOS not otherwise specified, SD standard deviation
a The 2 weeks preceding or following the index visit were accepted as baseline measurement (measurement was available for 279 patients in the 
originator cohort and 307 patients in the biosimilar one)
Characteristics Originator N = 423 (%) Biosimilar N = 444 (%) p value
Prevalent users 377 (89.1) 388 (87.4) 0.4
Incident users 46 (10.9) 56 (12.6)
Gender
 Male 270 (63.8) 273 (61.5) 0.5
 Female 153 (36.2) 171 (38.5)
Age, years (median; IQR) (64; 53–75) (76; 68–81) <0.05
Age classes, years
  ≤ 60 158 (37.4) 55 (12.4)
 61–70 101 (23.9) 79 (17.8) <0.05
 71–80 109 (25.8) 186 (41.9)
  ≥ 81 55 (13.0) 124 (27.9)
Dry weight, kg (mean ± SD) 68.1 ± 16.2 68.0 ± 14.9 0.9
Dialysis duration, months (median; IQR) (36; 15–82) (28; 11–66) 0.002
Previous renal transplant 60 (14.2) 17 (3.8) <0.05
Previous peritoneal dialysis 40 (9.5) 40 (9.0) 0.8
Vascular access
 Arteriovenous fistula 319 (75.4) 275 (61.9)
 Venous catheter 81 (19.1) 155 (34.9) <0.05
 Not specified 23 (5.4) 14 (3.2)
Dialysis sessions per week
 Two 26 (6.1) 44 (9.9)
 Three 382 (90.3) 390 (87.8) 0.07
 Not specified 15 (3.5) 10 (2.3)
Waiting list for transplant
 Yes 77 (18.2) 17 (3.8)
 No 329 (77.8) 423 (95.3) <0.05
 Not specified 17 (4.0) 4 (0.9)
Diagnosis leading to renal failure
 Diabetic nephropathy 66 (15.6) 61 (13.7) 0.4
 Glomerulonephritis 56 (13.2) 45 (10.1) 0.2
 Polycystic kidney disease 34 (8.0) 33 (7.4) 0.7
 Hypertensive nephropathy 6 (1.4) 11 (2.5) 0.3
 Nephropathy NOS 109 (25.8) 136 (30.6) 0.1
 Other nephropathy 152 (35.9) 158 (35.6) 0.9
Comorbidities
 Hypertension 320 (75.7) 330 (74.3) 0.7
 Vascular disease 167 (39.5) 188 (42.3) 0.4
 Diabetes mellitus 121 (28.6) 155 (34.9) 0.05
 Heart failure 97 (22.9) 118 (26.6) 0.2
 Coronary heart disease 96 (22.7) 102 (23.0) 0.9
 Arrythmia 95 (22.5) 130 (29.3) 0.02
 Cerebrovascular disease 75 (17.7) 76 (17.1) 0.8
 Valvular heart disease 19 (4.5) 16 (3.6) 0.5
Prescription drugs
 Number of prescription drugs per patient (mean ± SD) 8.3 ± 4.9 7.9 ± 4.4 0.2
 Iron supplementation 120 (28.6) 127 (28.6) 0.7
Hemoglobina (mean ± SD) 10.9 ± 1.2 10.8 ± 1.3 0.7
Epoetin dosage at the study start, IU (mean ± SD) 5957 ± 3447 5426 ± 3176 0.02
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ascertained that their safety profiles were in line with other 
ESAs and with the data from pre-marketing studies [10, 11]. 
In particular, the PASCO I study was conducted for up to 
1 year among patients with renal anemia treated with an 
intravenous epoetin biosimilar [10]. The median age was 
similar to our findings, while other characteristics such as 
the proportion of patients with diabetes or cerebrovascular 
diseases differed significantly. We found a similar frequency 
of fistula and shunt malfunction (about 10% of patients); the 
differences observed in relation to other events may be due 
to different inclusion criteria. With regard to EPO-PASS, our 
study had a comparative design (enabling a direct compari-
son between epoetin alpha drugs), focused on more severe 
patients (CKD patients without dialysis were not included), 
and had a longer follow-up (12 vs 6 months) [11].
A recent large observational study based on the record 
linkage of different regional databases (the Electronic Thera-
peutic Plan Register, the Health Care Assistance File, the 
Mortality Information System, and the Hospital Informa-
tion System of the Lazio Region) did not find any difference 
between originator epoetin alfa and biosimilars on relevant 
effectiveness and safety outcomes measured during the fol-
low-up period in patients with CKD [12]. In this study, com-
paring the occurrence of a composite outcome (including 
all-cause mortality, blood transfusion, major cardiovascular 
events, and blood dyscrasia), the adjusted HR was 1.02 (95% 
CI 0.78–1.33). However, only a small number (154: 1.9%) of 
the 8161 CKD patients included had received an epoetin alfa 
biosimilar; moreover, even though many potential confound-
ers were taken into account, limited clinical information was 
available at baseline (e.g., dry weight, comorbidities, iron 
supplementation) because of the retrospective study design. 
In our study, we observed the same estimates in a popula-
tion of biosimilar users that was almost three times larger 
and for which individual clinical information was recorded 
at baseline and during the 1-year follow up by means of an 
ad hoc case report form. A recently published comparative 
study (involving 57 and 47 patients who received origina-
tor and biosimilar epoetins, respectively) found that both 
groups of products were equally effective and safe for the 
Fig. 2  Kaplan–Meier survival analysis for outcomes grouped into three major categories and considered all together
373Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs
treatment of anemia in patients with CKD [13]. However, in 
the cohort treated with one of the originator epoetins, only 
six patients were receiving epoetin alpha, thus limiting the 
transferability of the comparison between originator epoetin 
alpha and biosimilars.
We found that patients who received biosimilars were 
significantly older, with more comorbidities, and were 
more likely not to be included on the transplant wait-
ing list than those treated with the originator. This partly 
reflects the results shown in other studies where patients 
receiving biosimilar ESAs were slightly older and with 
more comorbidities such as diabetes [1, 13]. These obser-
vations may suggest that doctors who are concerned with 
the benefit–risk profile of biosimilars might preferen-
tially select the originators to treat younger and healthier 
patients.
4.2  Implications for Clinical Practice and Health 
Systems
The European Medicines Agency (EMA) was the first regu-
latory authority in 2005 to clarify the general principles to 
be applied to a biological medicinal product claiming to be 
similar to another one already on the market [14]. However, 
the evaluation of biosimilar medicines for authorization pur-
poses by the EMA does not include recommendations on 
whether a biosimilar should be used interchangeably with its 
reference medicine. Consequently, any recommendations for 
switching are within the remit of the EU member states [15].
The issue of biosimilar use is still a matter of debate, 
at least in Italy: the various scientific societies [3], patient 
associations [16], and political authorities [4, 17] operating 
at the local level express different positions, therefore con-
tributing to the caution of clinicians. For instance, while our 
study was ongoing in 2014, the Italian Society of Pharma-
cology (SIF) published a working paper suggesting the need 
to carry out additional studies gathering real-life data on the 
comparative safety and efficacy of originator and biosimi-
lar ESAs [3]. Moreover, Italian consumption data showed a 
modest use of biosimilar epoetins, which accounted for only 
37% of the total defined daily dose per 1000 inhabitants per 
day in 2016, although an increase of 20% was observed from 
2015 to 2016 [18].
Our study involved only four Italian regions, accounting for 
about 15% of the Italian population. However, there is no rea-
son to expect that any clinical characteristics associated with 
the geographical area would modify the estimated safety of 
the epoetin originator and biosimilars. Therefore, the findings 
of our study should contribute to reassuring physicians about 
the equivalence of the epoetin alfa originator and biosimi-
lars. The analysis of the available evidence accumulated dur-
ing almost 10 years of use, in addition to post-authorization 
Table 2  Frequency distribution of safety outcomes by ESA exposure status
CI confidence interval, ESA erythropoiesis-stimulating agents, Hb hemoglobin, HR hazard ratio
a HRs were adjusted for age, vascular access, vascular disease, cerebrovascular disease, heart failure, diabetes, diabetic and hypertensive 
nephropathy, glomerulonephritis and epoetin dosage at the study start. Hb levels at baseline were not included in the final model since no differ-
ence in the two cohorts of users was observed
Originator Biosimilar Unadjusted HR 95% CI Adjusted  HRa 95% CI
Person-months 3295 3668
Any outcomes 123 151 1.1 (0.9–1.4) 1.0 (0.7–1.3)
Infections 42 58 1.3 (0.9–1.9) 0.9 (0.6–1.5)
 Other infections 18 30 1.5 (0.8–2.7) 1.3 (0.7–2.4)
 Respiratory infections 15 17 1.0 (0.5–2.1) 1.0 (0.5–2.1)
 Sepsis 9 11 1.1 (0.5–2.7) 0.9 (0.3–2.2)
Cardio and cerebrovascular events 42 50 1.1 (0.7–1.6) 0.9 (0.6–1.5)
 Bleeding 15 13 0.8 (0.4–1.6) 0.9 (0.4–2.0)
 Arrhythmia 3 12 3.2 (0.9–11.3) 3.2 (0.9–11.3)
 Peripheral ischemia 6 9 1.4 (0.5–3.9) 0.9 (0.3–2.5)
 Cerebral accident 6 6 0.9 (0.3–2.7) 0.6 (0.2–2.0)
 Coronary disease 6 4 0.6 (0.2–2.1) 0.7 (0.2–2.9)
 Thrombosis 6 3 0.4 (0.1–1.8) 0.7 (0.2–3.2)
 Heart failure 0 3
Problems related to dialysis device 39 46 1.1 (0.7–1.7) 1.1 (0.7–1.8)
Vascular complications of the fistula 26 34 1.2 (0.7–2.0) 1.1 (0.6–2.1)
Localized infections 8 6 0.7 (0.2–2.0) 0.6 (0.2–1.8)
Vascular complications of the catheter 5 6 1.1 (0.3–3.6) 1.5 (0.4–5.4)
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studies and spontaneous reports, may help scientific societies 
in making clearer statements about the equivalence of the two 
products. More generally, studies aimed at comparing origina-
tor and biosimilar drugs, far from being redundant, will rein-
force the credibility of the approval process of any biosimilar 
and thus boost confidence in their use.
The study had a limited power to detect a difference 
between the two formulations in terms of incidence of rare 
events such as hypersensitivity reactions (e.g., pure red cell 
aplasia [PRCA]). However, even though no event of PRCA 
was observed in our study, this information is of value in 
that it can contribute to a meta-analysis of studies that col-
lected similar data at an individual-patient level.
Given the observational nature of the study, no indica-
tion was provided to the participating centers about the 
use of different epoetin alpha products; since almost all the 
biosimilar prescriptions referred to one biosimilar epoetin, 
the observed findings cannot be extended to the other mar-
keted products. Moreover, our findings do not extend to the 
comparative safety of all marketed epoetins. Since the main 
objective of the study was to establish whether any clinically 
relevant difference could be highlighted between biosimilar 
and originator epoetin alfa products in current practice, we 
excluded from the analysis patients receiving other origina-
tor epoetins.
5  Conclusion
In conclusion, the study did not show any differences in the 
safety outcomes of originator and biosimilar epoetins. Even 
though relevant to the clinical setting of dialysis, our find-
ings provide further reassurance about the use of biosimilars 
in clinical practice.
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